Clinical Trials Sponsored by Angimmune LLC

Total 10746 results

Angimmune LLC
University of Louisville

Terminated

A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma

Melanoma

United States
Angimmune LLC
James Graham Brown Cancer Center

Unknown

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Stage IV Melanoma

United States
Afimmune

Terminated

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes (TRIAGE)

Type 2 Diabetes | Hypertriglyceridemia

Georgia, United States, Germany, Israel, Latvia, Switzerland
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD

Non Alcoholic Fatty Liver Disease

Georgia, Ukraine, United Kingdom
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Regimmune Corporation

Completed

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Prevention of aGVHD

United States
Altimmune, Inc.

Completed

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Obesity/Overweight

United States
Altimmune, Inc.

Completed

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Influenza

United States
Altimmune, Inc.

Completed

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Influenza A Subtype H5N1 Infection

United States
Afimmune

Recruiting

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

Sickle Cell Disease

United States
Afimmune

Terminated

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Severe Acute Decompensated Alcoholic Hepatitis

United States, Georgia
Afimmune

Completed

Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom
Altimmune, Inc.

Active, not recruiting

HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

Hepatitis B, Chronic

Spain, United Kingdom, Canada, United States, Germany
Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Terminated

NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

Coronavirus Infection

United States
Regimmune Corporation

Completed

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Graft Versus Host Disease

United States
Enimmune Corporation

Completed

A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects

Enterovirus Infections

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine

COVID-19

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety Evaluation of QIS in Healthy Subjects

Influenza
Adimmune Corporation

Completed

The Safety and Immune Response to Influenza Vaccination in Pregnant Women

Influenza

Taiwan
Adimmune Corporation

Completed

A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects

Influenza

Taiwan
Enimmune Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Enterovirus Infections

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Albimmune SL

Not yet recruiting

Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure. (ALBUMIM)

Septic Shock
Altimmune, Inc.

Completed

Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)

Healthy Volunteers

United States
Altimmune, Inc.

Completed

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes

United States
Altimmune, Inc.

Completed

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Non-Alcoholic Fatty Liver Disease

United States
Altimmune, Inc.

Completed

ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

NASH - Nonalcoholic Steatohepatitis

Australia
Altimmune, Inc.

Completed

Study of the Safety and Immunogenicity of NasoVAX Extension

Influenza

United States
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Altimmune, Inc.

Unknown

NasoShield Study of Safety and Immunogenicity (NasoShield)

Healthy Volunteers

United States
NatImmune A/S

Unknown

bLAC - Treatment of Cutaneous Warts in Immune Suppressed, Kidney Transplanted Patients

Cutaneous Warts

Denmark
Enimmune Corporation

Enrolling by invitation

A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children

Enterovirus Infections

Taiwan, Vietnam
Adimmune Corporation

Completed

Dose-finding Study for AdimrSC-2f Vaccine

COVID-19

Indonesia
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Non-Elderly Adult and Elderly Subjects

Influenza
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old

Influenza

Taiwan
Adimmune Corporation

Completed

A Pharmacovigilance Study for AdimFlu-S (A/H1N1) Influenza Vaccine in Pregnant Women

Adverse Drug Reactions
NImmune Biopharma

Completed

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

Ulcerative Colitis

United States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
NImmune Biopharma

Withdrawn

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis
NImmune Biopharma

Completed

Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

United States
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease

3

Subscribe